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Abstract
Existing analgesics are not efficacious in treating all patients with chronic pain and have harmful 
side effects when used long-term. A deeper understanding of pain signaling and sensitization 
could lead to the development of more efficacious analgesics. Nociceptor sensitization occurs 
under conditions of inflammation and nerve injury where diverse chemicals are released and 
signal through receptors to reduce the activation threshold of ion channels, leading to an overall 
increase in neuronal excitability [98; 28]. Drugs that inhibit specific receptors have so far been 
unsuccessful in alleviating pain, possibly because they do not simultaneously target the diverse 
receptors that contribute to nociceptor sensitization. Hence, focus has shifted towards targeting 
downstream convergence points of nociceptive signaling [98]. Lipid mediators, including 
phosphatidylinositol 4,5-bisphosphate (PIP2), are attractive targets as these molecules are required 
for signaling downstream of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases 
(RTKs). Furthermore, PIP2 regulates the activity of various ion channels [80]. Thus, PIP2 sits at a 
critical convergence point for multiple receptors, ion channels and signaling pathways that 
promote and maintain chronic pain. Decreasing the amount of PIP2 in neurons was recently shown 
to attenuate pronociceptive signaling and could provide a novel approach for treating pain. Here, 
we review the lipid kinases that are known to regulate pain signaling and sensitization and 
speculate on which additional lipid kinases might regulate signaling in nociceptive neurons.
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1. Introduction
Chronic pain affects approximately 100 million American adults, making it more prevalent 
than diabetes, cancer, and heart disease combined. In addition to being in a state of 
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and an inability to complete daily tasks, all of which lead to a significant decrease in overall 
quality of life [14]. Unfortunately, non-steroidal anti-inflammatory drugs (NSAIDs), 
acetaminophen (paracetamol), and opioid-based analgesics such as morphine—the current 
first-line therapeutics for pain—have harmful side effects while only providing partial relief 
[14]. The complexity of nociception, defined as detection of noxious stimuli, and subsequent 
pain processing, creates many challenges for analgesic drug discovery [28]. Current 
therapeutic inadequacies highlight the need to identify new molecular targets for analgesic 
drug development. In order to identify new therapeutic targets, the molecules and 
mechanisms associated with peripheral nociceptive signaling and sensitization need to be 
further elucidated [98].
Pain-producing heat, mechanical or chemical stimuli activate receptors, including Transient 
Receptor Potential (TRP) channels, which depolarizes pain-sensing neurons, also known as 
nociceptors [28]. Depolarization leads to action potential firing via the activation and 
interplay of voltage-gated sodium and potassium channels. The generated signal is then 
relayed from the periphery to the spinal cord via slowly conducting unmyelinated small-
diameter neurons (C-fibers) and more-rapidly conducting myelinated neurons (Aδ-fibers) 
[28]. Sensation carried by Aδ-fibers is robust, pricking and more accurate of the location of 
pain whereas C-fibers are thought to convey the sensation/perception of throbbing or 
burning pain, with relatively poor somatotopic localization [36].
Sensory inputs from Aδ-fibers synapse at lamina I whereas C-fibers synapse at lamina II of 
the dorsal horn, a region where some input integration and processing occurs [43]. The 
lateral thalamus, which has been implicated in sensory and discriminative aspects of pain, 
receives inputs from neurons in the dorsal horn via the lateral spinothalamic tract while 
medial thalamus and limbic structures receive inputs via the medial spinothalamic tract and 
spinobrachial tract and are believed to mediate the emotional and aversive components of 
pain [43]. Activity evoked by noxious stimuli can be modulated at the peripheral, spinal and 
supraspinal levels, which can significantly alter pain perception [57].
Under normal physiological conditions, nociceptors function as a defense mechanism to 
promote avoidance of painful, tissue-damaging stimuli [73]. This type of pain is called 
nociceptive or physiological pain [41; 28]. In contrast, persistent or chronic pain is normally 
uncoupled from a noxious stimulus and can be exacerbated by various mechanisms such as 
peripheral and central sensitization [43; 97]. Sensitization is characterized by a reduction in 
detection threshold and an increase in response to noxious stimuli which mediates two 
common symptoms of pain in humans, allodynia in which typically innocuous stimuli 
become painful and hyperalgesia in which a painful stimulus becomes more painful, 
respectively [97; 73; 6]. Sensitization of nociceptors occurs most commonly after 
inflammation and nerve injury [73; 6] and contributes to the two most common forms of 
chronic pain in humans, inflammatory and neuropathic pain, respectively [97]. Central 
sensitization reflects an amplification of pain signals in the central nervous system and takes 
place at the level of the dorsal spinal cord, in spinal neurons that are postsynaptic to 
nociceptive neurons, while peripheral sensitization occurs in DRG neurons and their axon 
terminals [97]. Central sensitization is often preceded by peripheral sensitization and is 
dependent upon activity from the central terminals of sensitized DRG neurons. Elevated 
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neurotransmission from the nociceptor terminals to dorsal horn neurons alters synaptic 
density, kinetics and threshold of activation, resulting in increase transmission of pain 
signals [97]. The focus of this review is on signaling mechanisms that mediate peripheral 
sensitization in DRG neurons.
1.1 Peripheral sensitization
Nociceptive, neuropathic, and inflammatory pain are mediated by several different 
molecular mechanisms; some of these mechanisms are unique to one type of pain while 
others are involved in multiple pain modalities [74]. Nerve injury and inflammation result in 
the release of multiple pronociceptive molecules, including bradykinin (BK), 
lysophosphatidic acid (LPA), adenosine triphosphate (ATP), prostaglandins (PGE2) and 
nerve growth factor (NGF) [28]. These ligands signal through a diverse set of Gq- and Gs-
coupled G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) to 
sensitize nociceptors [28]. Activation of Gq-coupled GPCRs via canonical Gq-coupling 
results in phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PIP2) to produce diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). 
IP3 binds to IP3 receptors on the endoplasmic reticulum (ER) to release calcium from 
intracellular stores, causing an increase in cytoplasmic calcium. DAG activates protein 
kinase Cs (PKCs) which can also activate the mitogen-activated protein kinase (MAPK) 
cascade. PKC and MAPK signaling cascades have been implicated in nociceptor 
sensitization associated with inflammatory and neuropathic pain [32]. Gs-coupled GPCRs 
can contribute to the PKC- pathway by exchange protein activated by cAMP (EPAC) 
activation of PLC [33]. In addition, RTKs recruit phosphoinositide 3-kinase (PI3K), a lipid 
kinase that phosphorylates PIP2 to generate phosphatidylinositol 3,4,5 triphosphate (PIP3) 
which activates Rac-alpha serine/threonine kinase (Akt or also known as protein kinase B, 
PKB) [101]. Importantly, downstream effector activation by GPCRs and RTKs can 
potentiate the activity and expression of a variety of ion channels and modulate the 
hyperexcitability of nociceptors following nerve injury and inflammation (Figure 1). 
Nociceptor sensitization goes beyond acute modification of ion channels and includes the 
generation of a “primed state”, a state where nociceptors are primed for activation but are 
inactive without overt stimulation [32]. This “primed state” is primarily mediated by PKC 
epsilon (ε) where rearrangement of cellular cytoskeleton, modulation of subcellular 
compartments and extracelluar matrices is observed [32]. Due to text constraints, we will 
focus on the signaling-mediated modulatory effects on ion channel activity only.
Of particular interest to this review is the non-selective cation channel, transient receptor 
vanilloid 1 (TRPV1), which is selectively expressed in the small and medium diameter 
unmyelinated sensory neurons. Capsaicin, noxious heat (>43°C), protons, ethanol, and many 
endogenous lipid metabolites can activate TRPV1 channels to allow cation influx, leading to 
membrane depolarization and subsequently result in action potential firing [40]. TRPV1 
activity is also regulated by PIP2 [68; 49]. Although the TRPV1 channel is activated by 
noxious temperatures (>43°C), during tissue injury and inflammatory conditions, the 
thermal activation threshold drops well below normal physiological temperatures, which 
serves as the cellular basis for inflammatory thermal hyperalgesia [41]. The reduction in 
activation threshold is due to post-translational modulation of TRPV1 by various kinases 
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such as PKA, PKC and Proto-oncogene tyrosine-kinase Src [8; 63; 7; 39; 104]. Activation of 
p38 MAPK through NGF signaling, as well as prolonged activation of PKC has been 
reported to enhance the expression of TRPV1 channel protein, thereby playing a role in 
nociceptor sensitization [38; 15; 102]. Indeed, mice lacking the TRPV1 gene do not develop 
inflammatory thermal hyperalgesia, and show modest impairment of noxious acute heat 
sensitivity [12; 17].
In addition to TRP channels, a variety of ion channels are responsible for regulating 
neuronal excitability—and more importantly hyperexcitability following nerve injury and 
inflammation—via mechanisms that are both independent of and dependent upon 
modulation by GPCRs and RTKs [23; 94]. Furthermore, an increase in excitability is crucial 
for prolonged nociceptive sensitization and persistent pain [6; 23; 28]. Many different 
classes of ion channels regulate neuronal excitability including sodium, potassium, calcium 
and hyperpolarization-activated (non-specific cation) channels [25; 26; 80; 6; 28]. Although 
a review of the functions of each of these ion channels is beyond the scope of this review, it 
is important to note that many of these ion channels depend on PIP2 for activity [25; 80; 23; 
81] (Figure 1).
One important commonality between GPCR-, RTK- and ion-channel mediated nociceptive 
signaling and sensitization is their dependence upon the lipid second messenger, PIP2 
(Figure 1). PIP2 regulates TRPV1 as well as other ion channels responsible for the 
regulation of neuronal excitability and is a critical component of the Gq-coupled GPCR and 
RTK signaling pathways, which mediate nociceptive sensitization following nerve injury 
and inflammation. Thus, PIP2 sits at a critical convergence point for many pain promoting 
pathways.
1.2 Phosphatidylinositol (4,5)-bisphosphate (PIP2)
Although PIP2 is only a minor constituent (<1%) of the plasma membrane, it is very 
important to a multitude of cellular processes and serves as prerequisite to other regulatory 
lipids in the phosphatidylinositol (PI) synthetic cascade [54; 103] (Figure 2). Many of the 
mentioned processes in section 1.1 are dependent upon adequate PIP2 synthesis via 
phosphatidylinositol kinases. Type 1 phosphatidylinositol 4-phosphate 5-kinases (PIP5KIs) 
and type 2 phosphatidylinositol 5-phosphate 4-kinases (PIP4KIIs) synthesize PI(4,5)P2 by 
phosphorylating phosphatidylinositol 4-phosphate, [PI(4)P] and phosphatidylinositol 5-
phosphate [PI(5)P], respectively (Figure 2). PI(4)P is the most abundant 
monophosphoinositide and is present at 10-fold greater concentrations than PI(5)P in 
erythrocytes, suggesting that PIP5KIs are the predominant PIP2 synthesizing enzymes [46]. 
It must be noted that PIKfyve can also phosphorylate phosphatidylinositol (PI) to generate 
PI(5)P that is subsequently phosphorylated by PIP4Ks to generate PI(4,5)P2, and 
phosphatidylinositol 3-phosphate, PI(3)P to form PI(3,5)P2. However, it has been shown 
that PIP5KI generation of PI(4,5)P2 is the major regulatory mechanism for GPCRs and ion 
channels [92; 80; 103] (Figure 2).
Rapid synthesis of PIP2 by activated lipid kinases has been suggested to feed into PIP2-
mediated pathways to amplify signaling downstream of stimulated receptors in non-neuronal 
cells [91; 61]. A similar mechanism could be at play in nociceptive neurons but further 
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studies will be required for confirmation. As lipid kinases gain recognition for their ability to 
alter pain sensitivity, we review the roles of various lipid kinases in regulating pain signaling 
and sensitization, with a primary focus on TRPV1 activity.
2. Lipid kinases that regulate nociceptive sensitization
2.1 Phosphoinositide 3-kinases (PI3Ks)
PI3Ks are the most studied group of lipid kinases. There are 3 classes of mammalian PI3Ks. 
Class I kinases (4 genes that give rise to α,β,δ and γ isoforms) are receptor-regulated 
PI(4,5)P2 kinases that produce PI(3,4,5)P3. Class II kinases (3 genes that give rise to α,β and 
γ isoforms) are larger monomeric enzymes known as PI3K-C2 kinases that phosphorylate PI 
to generate PI(3)P, and phosphorylate PI(4)P to generate PI(3,4)P2 (Figure 2; table 1). Class 
III kinase (only one isoform) is the “housekeeping” PI-specific enzyme responsible for 
generating PI(3)P. This review focuses on class 1 PI3Ks as their involvement in regulating 
receptor-activated signaling is well-established.
PI3Ks are comprised of 2 subunits, a catalytic subunit which binds to PIP2 and 
phosphorylates at the 3′ position and a regulatory subunit, which recognizes phosphorylated 
tyrosine residues and binds to SRC homology 2 (SH2) domains [85]. While all PI3K 
isoforms have a p110 (protein with molecular weight of 110 kilodaltons, kDa) catalytic 
subunit, PI3Kα, β and δ binds to a p85 (protein with molecular weight of 85 kDa) regulatory 
subunit whereas PI3Kγ binds to a p101 (protein with molecular weight of 101 kDa) 
regulatory subunit [85]. SH2 domains on the p85 regulatory subunit allow for interaction 
with phosphorylated tyrosine in membrane-associated proteins such as RTKs [108], 
recruiting p110 to the membrane to phosphorylate PIP2 to generate PIP3 [85]. A well-
studied example is the nerve growth factor (NGF)-TrkA receptor-PI3K signaling cascade. 
NGF is released in the vicinity of peripheral nerve endings during inflammation and 
sensitizes TRPV1 responses via activation of its receptor tyrosine kinase, TrkA, which 
subsequently recruits PI3K [76; 10]. PI3K binds to TRPV1 directly via its p85α subunit, 
which presumably recognizes the phosphorylated Y200 of TRPV1, to enhance TRPV1 
surface trafficking upon NGF stimulation of TrkA in DRG neurons [78]. Furthermore, PI3K 
sensitizes TRPV1 via activation of extracellular signal-regulated kinase (ERK) in sensory 
neurons and mediates NGF-induced inflammatory heat hyperalgesia and mechanical 
hyperalgesia [108; 51; 107]. Besides NGF-TrkA induced TRPV1 sensitization, PI3K 
recruitment of Akt/PKB also contributes to neuropathic pain induced by spinal nerve 
ligation and mechanical hypersensitivity induced by capsaicin in rats [20; 82; 101]. PI3K is 
also a major factor in central sensitization after noxious inflammatory stimuli [65]. Hence, 
inhibiting class I PI3Ks could provide a way to attenuate nociceptive sensitization.
However, pan-PI3K inhibitors, such as wortmannin and LY29002 (Table 1), may produce 
unwanted side effects due to the expression of class I PI3K in various cell types. Therefore, 
it is important to study the expression patterns of these isoforms and fully dissect the 
signaling pathways that each is involved in. PI3Kα, β and γ but not δ are expressed in DRGs 
[45; 5]. PI3Kα is ubiquitously expressed in sensory neurons. PI3Kβ is expressed in spinal 
cord dorsal horn neurons and enhances AMPA receptor trafficking upon inflammation, 
resulting in increase excitatory synaptic transmission [45]. PI3Kδ is reportedly not expressed 
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in the DRG but is found in astrocytes in the spinal cord dorsal horn [45]. Even though this 
isozyme does not seem to regulate nociceptive sensitization, it has important roles during 
development and in nerve regeneration after injury [21]. The only GPCR-coupled PI3K, 
PI3Kγ, is expressed in nociceptive neurons and has been implicated in morphine-induced 
peripheral analgesia and tolerance [16; 42]. Surprisingly, PI3Kγ knockout (Pik3cg−/−) mice 
exhibit enhanced responses to heat and capsaicin, suggesting that PI3Kγ acts as a negative 
regulator of thermal and TRPV1 responses [60]. Interestingly, antagonism of this isozyme 
with a specific inhibitor in the periphery (via intraplantar injections) was shown to be anti-
allodynic in a carrageenan-induced allodynia model [45]. The earlier finding of PI3Kγ 
negatively regulating TRPV1 activity only focused on acute thermal nociception and 
TRPV1 channel activity but did not look at the role of PI3Kγ in NGF-induced TRPV1 
sensitization or in neuropathic and inflammatory pain models. The latter finding from a 
different group indicated that inhibition of PI3Kγ inhibited allodynia in a carrageenan-
induced inflammatory pain model. The difference in observations could be due to the mode 
of nociception being investigated. The prominent role of PI3Kγ in positively regulating 
GPCR-signaling may overrule its negative effects on TRPV1 activity.
2.2 Phosphotidylinositol-4 kinases (PI4Ks)
PI(4)Ks phosphorylate PI to generate PI(4)P, the immediate precursor for PI(4,5)P2 (Figure 
2). Furthermore, PI(4)P itself is essential for TRPV1 activity as its depletion reduces the 
channel’s response to capsaicin [48]. There are 2 classes of mammalian PI4Ks, wortmannin-
sensitive class III enzymes, PI4KIIIα and PI4KIIIβ, and wortmannin-insensitive class II 
enzymes, PI4KIIα and PI4KIIβ. Class III enzymes exhibit a higher degree of similarity to 
PI3Ks, thus likely contributing to their sensitivity to wortmannin [55]. The subcellular 
location of these isozymes has been extensively characterized in various cell types. Their 
subcellular location governs the intracellular trafficking processes in which they are 
involved [13; 55; 56]. However, the functions of these kinases in regulating nociceptive 
sensitization in peripheral sensory neurons are unknown. Moreover, it is unknown which 
PI(4)Ks are expressed in DRG neurons. Interestingly, PI4K-mediated PIP2 production is 
crucial for the adaptation (response magnitude diminishes with sustained presence of 
stimulus, also known as desensitization) of ion channels such as inward-rectifier potassium 
channels (Kir) and voltage-gated potassium channels (Kv) in rat taste receptor cells, 
suggesting a plausible role for PI4Ks in regulating adaptation of Kv channels in pain-sensing 
neurons as well [106]. Prevention of desensitization of Kv channels via inhibition of PI4K 
could lead to decrease in neuronal excitability.
PI4KIIIα and PI4KIIα are the primary producers of plasma membrane PI(4)P [59; 58; 29; 
4]. Both kinases are widely expressed in mammalian tissues, with enrichment in the brain. 
PI4KIIIα is primarily localized to the ER and Golgi membranes whereas PI4KIIα is 
expressed on golgi networks and endosomes [29; 2]. Although they are primarily localized 
within intracellular membranes, they replenish the PI(4)P pools at the plasma membrane 
with PI4KIIIα shown to be essential for the maintenance of GPCR-responsive pool of 
PI(4)P [86; 3]. Minor axon loss was observed in DRG neurons of PI4KIIα knockout 
(Pi4k2a−/−) mice, suggesting that another PI4K regulates the majority of PI(4)P production 
in peripheral neurons [77]. PI4KIIIα conditional knockout in primary cultures of mouse 
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embryonic fibroblasts (MEFs) led to significant reduction in PI(4)P levels and plasma 
membrane PI(4,5)P2 levels even though global PI(4,5)P2 levels were only modestly reduced 
due to compensatory upregulation of PIP5KI expression [59]. Studies are still needed to 
evaluate inhibition of PI4KIIIα as an approach to reduce TRPV1 activity via reduction in 
PI(4)P levels. The dosing and route of administration of PI4KIIIα-specific inhibitors may be 
limited as conditional PI4KIIIα knockout mice develop lethal gastrointestinal disorders [84]. 
That said, the deletion of a gene in an entire organism after development could still be 
highly detrimental whereas an inhibitor administered at a specific site (such as intrathecal or 
topical) limits the exposure of the drug and may reduce unwanted side effects.
PI4KIIIβ is localized to the ER and Golgi membrane where it mediates endosomal/vesicular 
trafficking and perhaps plays a role in synaptic development and plasticity [27; 31; 79]. 
PI4KIIβ is mainly cytosolic and its translocation to the plasma membrane is promoted by 
platelet-derived growth factor [93]. PI4KIIβ activity is enhanced upon membrane insertion. 
It would be interesting to investigate if other growth factors such as NGF could induce a 
similar increase in PI4KIIβ membrane translocation and enhancement in activity in DRG 
neurons. The resultant upregulation of PI(4)P production and subsequent increase in PIP2 
pools could serve as a mechanism to amplify pronociceptive signaling by NGF.
2.3 Type 1 Phosphatidylinositol 4-phosphate 5-kinases (PIP5KIs)
The subsequent step of producing PIP2 from PI(4)P is mediated by PIP5KIs (Figure 2). 
There are three mammalian PIP5KI isozymes: PIP5KIα, PIP5KIβ, and PIP5KIγ (Figure 2). 
The three isozymes are >80% identical at the amino acid level within the kinase catalytic 
domain. However, they have very little sequence homology within their N and C termini; 
these isozyme-specific regions allow differentiated functions of each isoform within cells 
[34; 100]. Each isoform has differential expression within cells and across murine tissues. It 
must be noted that human PIP5KIα is homologous to murine PIP5KIβ and human PIP5KIβ 
is homologous to murine PIP5KIα. PIP5KIα is ubiquitously expressed in murine tissue, is 
primarily expressed in the nucleus, and translocates to the membrane following receptor 
activation [34; 19; 100]. PIP5KIβ is also ubiquitously expressed in murine tissue but is 
located in the perinuclear region [19]. Unlike ubiquitously expressed PIP5KIα and PIP5KIβ, 
PIP5KIγ is expressed predominantly in neuronal tissue, with some expression detected in 
the lung and kidney. PIP5KIγ localizes to the cytoplasm, plasma membrane and intracellular 
membranes [95; 18; 92].
Characterization of PIP5KIα and PIP5KIβ has been carried out utilizing a variety of cell 
types and roles in membrane ruffling, endocytosis, and actin dynamics have all been 
elucidated [53; 52]. It is common for PIP5KIα and PIP5KIβ to have overlapping functions; 
however, like the specialized expression profile of PIP5KIγ, it is rare that PIP5KIγ shares 
common functionality with PIP5KIα and PIP5KIβ [53; 52]. Endocytosis is the one function 
in which all three isozymes play a role; however, it is suggested that PIP5KIγ has a 
specialized role in interacting with adaptor protein 2 (AP-2) in this process [1; 53]. 
Furthermore, in bone marrow macrophages, PIP5KIα and PIP5KIγ have very distinct 
functions that mediate different steps in phagocytosis [53; 52]. The role of PIP5KIγ has 
primarily been studied in cortical synaptic transmission [18], GPCR-mediated signaling 
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[92], regulation of focal adhesions [47], and AP-2 mediated endocytosis [1]. Moreover, the 
functions of PIP5KIγ can be further differentiated by the involvement of the two different 
splice isoforms, PIP5KIγ635 and PIP5KIγ661. PIP5KIγ635 is the primary splice variant 
responsible for the regulation of GPCR-mediated signaling whereas PIP5KIγ661 is the 
primary splice variant responsible for the interactions with talin and AP-2 which mediate 
endocytosis and focal adhesions [47; 92; 1; 53].
Our recent study indicates that PIP5KIγ is the predominant PIP2-producing PIP5K1 in DRG 
neurons and is an important regulator of nociceptive signaling and sensitization [99]. 
Thermal and mechanical hypersensitivity in models of neuropathic and inflammatory pain as 
well as TRPV1 sensitization were significantly reduced in PIP5KIγ heterozygous 
(Pip5k1c+/−) mice. Constitutive PIP5KIγ homozygous knockouts (Pip5k1c−/−) are 
embryonically lethal [99], and hence should not be studied. We independently validated our 
genetic observations with a small molecule inhibitor of PIP5KIγ, UNC3230 (Table 1). 
Intrathecal delivery of UNC3230 had induced antinociceptive effects in our rodent pain 
models, recapitulating the antinociceptive phenotypes observed in Pip5k1c+/− mice, 
suggesting that localized inhibition of PIP5KIγ in adults is sufficient to reduce nociceptive 
sensitization [99].
A recent functional genomics study identified phospholipid signaling and lipid kinases as 
key regulators of heat nociception in flies [60]. It was also found that PIP5KIα knockout 
(Pip5k1a−/−) mice displayed hypersensitivity to noxious heat and capsaicin but the precise 
underlying mechanism is unknown. PIP5KIα is expressed at much lower levels in DRG and 
does not contribute to PIP2 levels in the nervous system [89]. Given the sometimes differing 
or opposing roles of PIP5KIα and PIP5KIγ in the same processes [53; 52; 87; 62; 61], it is 
reasonable to speculate that PIP5KIα and PIP5KIγ may have opposing functions in DRG 
neurons. Furthermore, given the complexity of nociceptive signaling and the low level of 
expression of PIP5KIα in DRG neurons, PIP5KIα could be modulating nociceptive 
processes at the level of the spinal cord or brain.
3. Additional lipid kinases that might regulate nociceptive signaling and 
sensitization
3.1 PIKfyve generates PI(3,5)P2
Besides producing PI(5)P from PI, PIKfyve also phosphorylates PI(3)P to generate 
PI(3,5)P2. PIKfyve negatively regulates exocytosis in the neurosecretory cells [64] while 
levels of PI(3,5)P2 are important in maintaining the health of peripheral neurons [105]. 
Although their role in regulating peripheral nociceptor sensitization is unknown, PIKfyve 
has been shown to downregulate the expression of Cav1.2 in cortical neurons. Interestingly 
this voltage-gated calcium channel is upregulated in spinal dorsal horn in chronic 
neuropathic pain [22; 83].
3.2 Phosphatidylinositol 4-phosphate kinase (PIP4K)
As pools of PI(5)P are relatively low compared to PI(4)P, as studied in erythrocytes [46], 
PIP4Ks are assumed to not have a major role in regulating the levels of PI(4,5)P2 in cells. 
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Studies are required to identify their expression and role in regulating signaling in 
nociceptive neurons.
3.3 Diacylglycerol Kinase (DGKs)
PIP2 hydrolysis by activated PLC produces DAG and IP3. DAG, which activates PKC, can 
be phosphorylated by DGKs to generate phosphatidic acid (PA). A study has shown that 
DGKí and ζ are expressed in the DRG but their roles in regulating GPCR signaling in DRG 
neurons remain uninvestigated [71]. Recently, we found that overexpression of DGKη leads 
to sustained GPCR signaling in HEK cells [69], suggesting that inhibition of DGKη, and 
possibly other DGK isoforms, may blunt GPCR signaling. Furthermore, DGKζ-produced 
PA can activate PIP5KIα, suggesting that DGK contributes to a forward feedback 
mechanism that can further enhance PIP2 production [50]. Hence, inhibition of DGKs could 
serve as an approach to desensitize and reduce signaling in DRG neurons, provided future 
studies confirm a regulatory role in nociceptive signaling similar to those observed in HEK 
cells.
4. Future Directions
Bypassing nociceptor and receptor diversity by targeting convergence points downstream of 
multiple pronociceptive receptors and ion channels provides a promising approach to inhibit 
nociceptive sensitization. Lipid second messengers such as PIP2 are attractive candidates 
due to their involvement in regulating the activity of various ion channels and serving as 
precursors for downstream effectors of GPCR- and RTK- signaling pathways. Targeting 
lipid kinases that produce these regulatory lipid second messengers could provide novel 
approaches to attenuate pain signaling (Figure 3). Many of the proposed mechanisms that 
involve lipid kinases in this review are speculative due to a lack of understanding of their 
expression and function in DRG neurons. This area is thus ripe for further research and 
therapeutic intervention, particularly given that kinases are highly druggable targets. 
However, caution is warranted when targeting these lipid kinases as they are widely 
expressed and are involved in regulating many physiological processes.
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Figure 1. GPCR- and RTK- mediated signaling that leads to sensitization of nociceptors
Nociceptive sensitization is dependent on PIP2-sensitive GPCRs, RTKs and ion channels 
that mediate hyperexcitability following nerve injury and inflammation. Activation of 
GPCRs leads to PKC-mediated enhancement of TRPV1 and Tetrodotoxin (TTX)-resistant 
Voltage-gated Sodium Channel (NaV) activity. Stimulation of RTKs leads to activation of 
the PI3K/PDK1/Akt signaling cascade.
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Figure 2. Phosphatidylinositol (PI) synthetic pathways
Phosphatidylinositol (PI) can be phosphorylated at the D3, D4 and D5 position of the 
inositol ring by PI3K, PI4K and PIKfyve respectively. The majority of all 
phosphatidylinositol 4,5-bisphosphate (PIP2) is synthesized via phosphorylation of PI(4)P 
by PIP5KIs. PIP2 can undergo further phosphorylation by class I PI3Ks to generate PIP3. R2 
and R1 are the fatty acid chains that make up diacylglycerol (DAG). Phosphate groups are 
red. Figure based on reactions catalyzed in vivo [70]. Image adapted from [75]. Gene names 
for respective kinases are shown in parentheses.
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Figure 3. Lipid kinases (in blue) that regulate levels of PIP2 (PI(4,5)P2) could affect nociceptive 
sensitization when inhibited or genetically deleted
PIP2 levels decrease significantly via inhibition of PIP5K and modestly when PI4K is 
inhibited[59]. Whether PIKfyve and PIP4K contribute to PIP2 levels in DRG neurons is 
unknown. PI3K inhibition leads to significant attenuation of NGF-induced TRPV1 
sensitization. DGK phosphorylation of DAG produces PA, which has been implicated in 
PIP5K activation, suggesting a feedforward mechanism for PIP2 signaling.
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Table 1
Representative lipid kinase inhibitors
Drug Kinases inhibited References
Wortmannin PI3K and class III PI4Ks Powis et al. (1994) [67] Nakanishi et al. (1995) [58]
GDC-0941 PI3K Folkes et al. (2008) [24]
LY29002 PI3K Vlahos et al. (1994) [88]
Compound 15e PI3Kα Hayakawa et al. (2006) [30]
TGX221 PI3Kβ Jackson et al. (2005) [35]
CAL-101 PI3Kδ Lanutti et al. (2011) [44; 66]
AS252424 PI3Kγ Pomel et al. (2006) [66]
Phenylarsine Oxide (PAO) PI4K Wiedeman et al. (1996) [96]
PIK-93 PI4KIIIβ Burke et al. (2014) [11]
4-anilinoquinazolines PI4KIIIα Bianco et al. (2012) [9]
Adenosine Class II PI4Ks (low dose), Class III PI4Ks (high dose) Guo et al. (2003) [29]
SAR088 PIP4KIIβ Voss et al. (2014) [90]
UNC3230 PIP5K1γ Wright et al. (2014) [99]
YM201636 PIKfyve Jefferies et al. (2008) [37]
R59022 strongly inhibits DGKα, moderately inhibits DGKε and θ Sato et al. (2013) [72]
R59949 strongly inhibits DGKα, moderately inhibits DGKδ and κ Sato et al. (2013) [72]
Pain. Author manuscript; available in PMC 2016 April 01.
